ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mar, 16/11/2021 - 14:31
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Los ingresos operativos se situaron en 525,1 millones de euros en los nueve primeros meses de 2025, un descenso del 7% con respecto al...
15 min
06/11/2025
Madrid, España –21 de octubre de 2025. – Laboratorios Farmacéuticos Rovi, S.A. (en adelante, “ROVI”), compañía farmacéutica paneuropea...
3 min
21/10/2025
Laboratorios Farmacéuticos Rovi, S.A., comunica que, ROIS Phoenix Inc. (el “Comprador”), filial íntegramente participada por ROVI Pharma...
1 min
29/09/2025
shutterstock_1323088832.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 16 November 2021
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold a virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.